Pulse Biosciences (NASDAQ:PLSE – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.
Pulse Biosciences Price Performance
Shares of PLSE stock traded down $0.14 on Thursday, reaching $15.66. 282,108 shares of the company’s stock were exchanged, compared to its average volume of 194,251. The company’s fifty day simple moving average is $18.87 and its 200 day simple moving average is $18.18. Pulse Biosciences has a 52 week low of $6.60 and a 52 week high of $25.00.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
- Five stocks we like better than Pulse Biosciences
- Canada Bond Market Holiday: How to Invest and Trade
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Top 3 Beverage Stocks Pouring Out Profits
- Why Invest in 5G? How to Invest in 5G Stocks
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
